The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50
and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK),
in comparison to placebo and 200 mg entacapone (ENT).